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Background: The characteristics of phenotypes of elderly patients with asthma are unknown. The aim of
this study was to classify these phenotypes using lung function tests and images from high-resolution
computed tomography (HRCT), and to identify associations between clinical characteristics and
phenotypes.
Methods: A cross-sectional study was conducted in 165 elderly patients (>65 years of age) who un-
derwent a multidimensional assessment of clinical and functional status and comorbidity. The patients
were divided into three phenotypes: (1) asthma-predominant, (2) asthma-obstructive airway disease
(OAD) overlap without emphysema, and (3) asthma-OAD overlap with emphysema (asthma-emphysema
overlap) based on chest HRCT. A receiver operating characteristic (ROC) curve was constructed to eval-
uate the cutoff for differentiating between the two OAD phenotypes. Multivariate analysis was also used
to distinguish between these two phenotypes.
Results: The phenotypes were asthma-predominant in 48 patients (29%), asthma-OAD without
emphysema in 36 (22%), and asthma-emphysema in 81 (49%). Patients with asthma-emphysema were
more frequent smokers. In multivariate analysis, smoking status (odds ratio 2.92: 95% CI 1.21e7.00,
P ¼ 0.03) and % predicted FEV1 70% (odds ratio 3.18: 95% CI 1.13e8.92, P ¼ 0.03) differed signiﬁcantly
between the asthma-emphysema and asthma-OAD without emphysema phenotypes.
Conclusions: Half of elderly patients with asthma are characterized by asthma-emphysema overlap. Our
results showed that elderly patients with asthma who are smokers and have moderate or severe OAD are
also likely to have emphysema.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma is an allergic disease that commonly develops at a
young age, is characterized physiologically by reversible airﬂow
obstruction, and responds well to anti-inﬂammatory treatment. In
contrast, chronic obstructive pulmonary disease (COPD) is charac-
terized by incomplete reversible airﬂow limitation, is typicallyy Medicine and Allergology,
hi, Osaka-Sayama, Osaka 589-
.
ety of Allergology.
rgology. Production and hosting by Elsecaused by tobacco smoking, and develops at an old age. There is a
considerable pathologic and functional overlap between these two
heterogeneous disorders, particularly among the elderly, who may
have components of both diseases. This condition is referred to as
asthma-COPD overlap syndrome (ACOS), in which asthma and
COPD are at the opposite ends of the disease spectrum.1,2 ACOS is
deﬁned as a post-bronchodilator ratio of forced expiratory volume
in 1 s/forced vital capacity (FEV1/FVC) <0.7 in current international
guidelines.
The number of older people with asthma is likely to rise due to
the worldwide population trend for longevity and the dispropor-
tionate increase in people aged 65 years and older.3 This is a
concern because mortality in older people with asthma is highervier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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a diagnosis of asthma are associated with a greater decline in FEV1
in both smokers and nonsmokers5,6 and asthma is a risk factor for
chronic COPD.7 However, the characteristic features of worsening
asthma control in elderly patients are not well understood.8 Also,
since irreversible obstructive airway disease (OAD) often coexists
with asthma in elderly patients, the presence of accompanying
emphysema requires evaluation by diffusion capacity or computed
tomography (CT) of the lung.9 Therefore, the aims of this study
were to deﬁne phenotypic subgroups of asthma and determine the
proportion of elderly patients aged >65 years in each group, and to
characterizes the clinical features of these phenotypes based on
lung function and chest CT ﬁndings.
Methods
Subjects
A single-center cross-sectional study was conducted in the
outpatient department at Kinki University Hospital between
October 2011 and September 2012. The subjects were 170 patients
with asthma aged 65 years old who were recruited from the
Department of Respiratory Medicine and Allergology. Diagnoses of
asthma and COPD were made by the subjects' physician consistent
with the deﬁnitions for these diseases in the Global Initiative for
Asthma10 and the Global Initiative for Chronic Obstructive Lung
Disease11 guidelines, respectively. All subjectswere assessed at visits
in which the disease had been stable for at least 8 weeks since
exacerbation, which was deﬁned as an increase in symptoms
necessitating a course of oral corticosteroids and/or antibiotic ther-
apy. All subjects provided written informed consent and the study
was approved by the Kinki University Hospital ethics committee.
Objective and procedures
To identify the clinical characteristics of comorbidity of COPD in
elderly patients with asthma, the subjects were divided into three
phenotypes: asthma-predominant, based on the absence of airﬂow
obstruction; asthma-OAD overlap, deﬁned as irreversible airway
obstruction without emphysema on chest high-resolution CT
(HRCT); and asthma-emphysema overlap, a combination of airﬂow
obstruction and emphysema.
Measurements
Physicians interviewed each patient to establish details of
medical history, family history, smoking history and respiratory
symptoms based on questionnaires. Subjects were deﬁned as never,
former or current smokers of tobacco (cigarettes, cigars or pipes).
Cumulative cigarette consumption was calculated in pack-years,
with 1 pack-year equivalent to 20 cigarettes per day for 1 year.
Blood samples
Blood was collected for measurement of total serum IgE and
complete blood count. Total and speciﬁc IgE were measured with a
third-generation chemiluminescent enzyme immunoassay
(Immulite 2000; Siemens Medical, Deerﬁeld, IL, USA). Atopy was
deﬁned as any speciﬁc IgE to common allergen >0.35 kU/L.
Pulmonary function tests
Spirometry was performed with a portable spirometer (Minato,
Tokyo, Japan) according to American Thoracic Society (ATS)
criteria.12 FEV1 and FVC were measured and FEV1 was used to
evaluate airway obstruction. After several practice measurements
with a trained technician, measurements for data collection weretaken three times. The greatest FEV1 from acceptable tests for each
subject was selected. The subjects were instructed to take complete
inspirations and expirations that lasted approximately 3 s.13
Reversibility of the reduction in FEV1 was measured 15 min after
inhalation of 20 mg procaterol.
AHR is expressed as themethacholine concentration that caused
a 20% decrease in FEV1 from baseline (PC20). The test was admin-
istered at least 8 h after the last dose of short-acting bronchodila-
tors and 24 h after inhaled corticosteroids (ICS) or long-acting
bronchodilators.
The diffusion capacity of the lung for carbon monoxide (DLCO)
was determined using the single-breath method. Alveolar volume
(VA) was measured during the single-breath maneuver using he-
lium as the inert gas. A % predicted DLCO 80% indicates emphy-
sema of the lung. ATS guidelines were followed for all lung function
tests.14
Fraction of exhaled nitric oxide (FeNO)
FeNO was measured online by NOA280i (Severs, GE Analytical
Instruments, Boulder, CO, USA) at a constant expiratory ﬂow rate
(50 mL/s) before any forced expiratory maneuvers, consistent with
published guidelines.15 All readings were obtained by technical
staff.
High-resolution computed tomography (HRCT)
The severity of radiological emphysema on chest HRCT (2-mm
sections at 15-mm intervals) was visually assessed by three inde-
pendent pulmonologists using the Goddard scoring system.16 Six
images of three lung slices (the right and left lungs were evaluated
separately) were analyzed for each patient. Each image was clas-
siﬁed and scored as normal (score 0),5% affected (score 0.5),25%
affected (score 1), 50% affected (score 2), 75% affected (score 3)
and >75% affected (score 4). The mean score of the six images was
taken as representative of the severity of emphysema. Each image
was then classiﬁed as normal (score 0), very mild (>0 to0.5), mild
(>0.5 to 1), moderate (>1 to 2), and (E) severe (>2).
Emphysema was diagnosed as airway obstruction on a pulmo-
nary function test (FEV1/FVC <0.7) and the presence of emphysema
on a chest image (emphysema score >0).
Statistical analysis
Differences in continuous variables between groups were
analyzed by KruskaleWallis test followed by post hoc analysis by
Dunn test. For categorical variables, a c2 test (or Fisher exact test for
small proportions) was used, P < 0.05 was considered signiﬁcant. A
receiver operating characteristics (ROC) curve was constructed to
evaluate the best cutoff for differentiating asthma-emphysema
overlap from asthma-OAD overlap. Multivariate logistic regres-
sion analysis was used to distinguish asthma-emphysema from
asthma-OAD without emphysema, with the results reported as the
odds ratio (OR) with a 95% conﬁdence interval (CI). All analyses
were performed using SPSS ver. 19.0 (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics
Of the 170 elderly patients with asthma enrolled in the study,
we excluded ﬁve patients due to an absence of lung function tests
or HRCT, leaving 165 patients in the analysis. The demographic and
clinical features of the study population are shown in Table 1. There
were 92males (54.1%), the average agewas 73.8 ± 5.4 years old, and
89 patients (52.4%) had a smoking history, including 47% with >10
pack-years. An atopic dispositionwas present in 76 patients and the
Table 1
Clinical characteristics of elderly patients with asthma.
Item Data
Number of patients 165
Sex, % male 54%
Age, years 73.8 ± 5.4
Duration of asthma, years 16.4 ± 19.3
Smoking status
Never/former/current 78/75/12
>10 Pack-years, % 47%
Serum IgE level, IU/mL 493.4 ± 920.0
Atopic status, % 46%
Post-bronchodilator FEV1/FVC ratio 63.8 ± 12.5
% Predicted FEV1 80.1 ± 19.4
% Predicted FEV1 < 80%, % 47%
Reversibility, % 10%
%DLCO, % 120.6 ± 32.5
PC20, mg/mL 13.6 ± 19.4
FeNO, ppb 40.0 ± 38.8
Treatment, %
ICS/LABA/LAMA 6%
ICS/LABA 48%
ICS/LAMA 4%
ICS alone 43%
Abbreviations: DLCO, diffusion capacity of the lung for carbon monoxide; FeNO,
fraction of exhaled nitric oxide; FEV1, forced expiratory volume in one second; ICS,
inhaled corticosteroids; LABA, long-acting beta2-bronchodilator agonists; LAMA,
long-acting muscarinic antagonists; PC20, provocative concentration that causes a
positive reaction to a 20% fall in FEV1.
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FEV1 was 63.8 ± 12.5% and 70.9% of the patients had OAD. Themean
diffusion capacity of the lung indicated by %DLCO or %DLCO/VAwas
in the normal range, but the level of exhaled NO was elevated to
40.0 ± 38.8 ppb. Low attenuation areas (LAAs) on chest HRCT had aTable 2
Clinical characteristics of phenotypes of elderly patients with asthma.
Asthma-
predominant
Asthma-OAD
overlap
Asthma-emphysema
overlap
Number of patients
(%)
48 (29%) 36 (22%) 81 (49%)
Sex, % male 29% 36% 74%*
Age, years 73.3 ± 4.6 74.0 ± 6.6 73.8 ± 5.3
Duration of asthma,
years
13.0 ± 12.9 19.9 ± 14.2 16.1 ± 18.0
Smoking status
Never/former/
current
32/15/1 23/11/2 23/49/9
>10 Pack-years, % 29% 33% 63%*
Serum IgE level, IU/mL 345.0 ± 714.2 412.8 ± 507.3 613.6 ± 1133.0
Atopic status, % 35% 47% 52%*
Postbronchodilator
FEV1/FVC ratio
77.6 ± 5.5 63.4 ± 4.4** 55.9 ± 10.8**
% Predicted FEV1 93.8 ± 16.0 79.9 ± 15.5** 72.1 ± 18.5**
% Predicted
FEV1 < 80%, %
21% 50%* 62%*
Reversibility, % 4% 6% 10%**
%DLCO, % 119.3 ± 22.2 129.0 ± 32.0 117.6 ± 37.4
PC20, mg/mL 21.1 ± 21.7 39.1 ± 9.1 12.8 ± 19.1
FeNO, ppb 38.4 ± 40.0 55.6 ± 60.7** 33.7 ± 19.8
Treatment, %
ICS/LABA/LAMA 2% 0% 10%
ICS/LABA 36% 44% 57%
ICS/LAMA 2% 6% 3%
ICS alone 58% 50% 30%
Abbreviations: DLCO, diffusion capacity of the lung for carbon monoxide; FeNO,
fraction of exhaled nitric oxide; FEV1, forced expiratory volume in one second; ICS,
inhaled corticosteroids; LABA, long-acting beta2-bronchodilator agonists; LAMA,
long-acting muscarinic antagonists; PC20, provocative concentration that causes a
positive reaction to a 20% fall in FEV1.
*P < 0.05, **P < 0.01 vs. asthma-predominant by KruskaleWallis test followed by
post-hoc Dunn test.
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Fig. 1. %FEV1 (A), %DLCO (B) and FENO (C) for the asthma-predominant, asthma-OAD
overlap without emphysema, and asthma-OAD overlap with emphysema (asthma-
emphysema overlap) phenotypes. Bars show mean and standard deviation.low mean value of 2.3 ± 4.5 in the Goddard classiﬁcation. All pa-
tients were treated with ICS.Classiﬁcation of phenotypes of elderly patients with asthma
The elderly patients with asthma were classiﬁed into asthma-
predominant (n ¼ 48, 29%), asthma-OAD overlap (n ¼ 36, 22%),
and asthma-emphysema overlap (n ¼ 81, 49%) phenotypes
(Table 2). The asthma-emphysema overlap group had most males,
the highest rate of smoking >10 pack-years, and the most frequent
atopic status. The % predicted FEV1 in patients with asthma-
emphysema and asthma-OAD without emphysema was signiﬁ-
cantly lower than that in the asthma-predominant group
(P < 0.001). %DLCO in asthma-emphysema did not differ signiﬁ-
cantly from those for other phenotypes (Fig.1A, B). FeNO in asthma-
OAD without emphysema was signiﬁcantly higher than that in
asthma-emphysema (P ¼ 0.02) (Fig. 1C).
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To assess the characteristics of the three phenotypes, the pa-
tients were classiﬁed into ﬁve categories based on severity of
emphysema: 74 had no abnormal ﬁndings, 59 had very mild
emphysema, and 15, 11 and 6 patients had mild, moderate and
severe emphysema, respectively, based on the modiﬁed Goddard
classiﬁcation (Fig. 2). Ten patients in the asthma-predominant
group had very mild emphysema.
Discrimination of asthma-OAD without emphysema from asthma-
emphysema
A ROC curve was constructed to establish a cutoff to discrimi-
nate asthma-emphysema from asthma-OAD without emphysema.
The optimal cutoffs for % predicted FEV1 (Fig. 3A) and FeNO (Fig. 3B)
to discriminate between these phenotypes were 70% (sensitivity
64%, speciﬁcity 67%) and 70 ppb (sensitivity 62%, speciﬁcity 72%),
respectively. Age and atopic status were excluded in univariate
analysis of confounding factors associated with comparison of the
two phenotypes. In logistic regression analysis, smoking history
>10 pack-years (OR 2.92: 95% CI 1.21e7.00, P ¼ 0.03) and %pre-
dicted FEV1 70% (OR 3.18: 95% CI 1.13e8.92, P ¼ 0.03) (Table 3)
were associated with asthma-emphysema, and FeNO >70 ppb (OR
0.27: 95% CI 0.08e0.91, P ¼ 0.02) was a predictor for asthma-OAD
without emphysema.
Discussion
Elderly patients with asthma were classiﬁed into asthma-
predominant (29%), asthma-OAD overlap (22%), and asthma-
emphysema overlap (49%) phenotypes using pulmonary function
tests and chest HRCT. COPD is thought of as an overlap of chronic
bronchitis, emphysema and subtypes of asthma associated with
chronic airﬂow limitation. Snider et al. ﬁrst represented these
phenotypes in a non-proportional Venn diagram17 and the three
phenotypes of elderly patients with asthma in the current study are
shown in this style in Figure 4, based on the diagram produced by
the ATS.18 To the best of our knowledge, this study is the ﬁrst toA
. N
or
m
al
 
B
. V
er
y 
m
ild
C
. M
ild
 
E.
 S
ev
er
e
D
. M
od
er
at
e
D
is
tr
ib
ut
io
n 
(p
er
so
ns
)
0
10
20
30
40
50
60
70
80
Fig. 2. Distribution of the severity of emphysema on chest HRCT in elderly patients
with asthma. The severity of emphysema on HRCT was assessed using the modiﬁed
Goddard scoring system. The mean score of six images for each patient was classiﬁed
as (A) normal (score 0), (B) very mild (>0 to 0.5), (C) mild (>0.5 to 1), (D) moderate
(>1 to 2), and (E) severe (>2). Ten patients in the asthma-predominant group had
very mild emphysema.
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Fig. 3. ROC analysis for distinguishing between asthma-emphysema overlap and
asthma-OAD overlap. The cut-offs separating the two groups were %FEV1 of 70% (A)
and FENO of 70 ppb (B).classify elderly patients with asthma using pulmonary function
tests and chest HRCT.
The phenotype of asthma-emphysema was characterized by
mild LAAs with irreversible airway obstruction. In addition, 37% of
patients with this phenotype were non-smokers and approxi-
mately half were atopic. Braman et al.19 found that non-smoking
patients with long-term asthma might develop chronic persistent
airﬂow obstruction and thereby mimic chronic bronchitis and
emphysema (COPD). The characterization of this phenotypemay be
partially explained by the “Dutch hypothesis”,20 which states that
asthma and AHR predispose patients to COPD later in life. Some
LAAswere present in the asthma-emphysema group on chest HRCT,
but there was no signiﬁcant difference in diffusion capacity,
compared with the asthma-predominant group (Table 2). This may
be explained by the very mild to mild emphysema. Donohue et al.
Table 3
Factors distinguishing between asthma-OAD without emphysema and asthma-
emphysema (ACOS).
Confounding
factor
Univariate analysis OR
(95% CI), P-value
Multivariate analysis
OR (95% CI), P-value
Age, >74 years 1.27 (0.58e2.78), 0.56 e
Smoking status 3.40 (1.49e7.77), 0.004 2.92 (1.21e7.00), 0.02
Atopic status 1.20 (0.55e2.64), 0.64 e
% Predicted FEV1, <70% 4.21 (1.58e11.2), 0.004 3.18 (1.13e8.92), 0.03
FeNO, >69 ppb 0.17 (0.05e0.55), 0.003 0.27 (0.08e0.91), 0.02
Abbreviations: FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory vol-
ume in one second.
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life.21 Our results showed that 20% of asthma-predominant patients
(who had no OAD) had very mild LAA. This implies that there is a
different pathophysiology of LAAs between asthma-emphysema
and COPD only.
From the point of view of phenotypic subgroups of COPD, it was
reported that FeNO was one of useful biomarkers to distinct ACOS
from COPD.22 In our results, FeNO might contribute to distinguish
between asthma-OAD overlap without emphysema and asthma-
emphysema overlap (ACOS). The phenotype of asthma-OAD over-
lap without emphysema was characterized by eosinophilic airway
inﬂammation. This phenotype comprised remodeling asthma and
chronic bronchitis associated with COPD; however, in many cases it
is very difﬁcult to differentiate patients with remodeling asthma
whose airﬂow obstruction does not remit completely from patients
with chronic bronchitis. From sputum cytokine proﬁling, there are
three distinct and overlapping groups of subjects with asthma and
COPD: cluster 1: asthma predominant, eosinophilic, high Th2 cy-
tokines; cluster 2: asthma and COPD overlap, neutrophilic; and
cluster 3: COPD predominant, mixed eosinophilic and neutro-
philic.23 Biomarkers for discrimination of the phenotype of asthma-
OAD without emphysema are required.
Interestingly, the phenotype of asthma-OAD without emphy-
sema had an earlier age of onset of asthma, a longer disease
duration and worse lung function at baseline (FEV1 79.9% pre-
dicted) compared to the asthma-predominant (93.8% predicted)
group, in agreement with the ﬁndings of de Marco et al. for ACOS.24
Airway remodeling occurs throughout the respiratory tract, but: 
: 
Chronic bronchitis 
(CB)
Emphysema
Asthma
Obstructive airway 
disease (OAD)
: 
Asthma-predominant (n=48)
Asthma-OAD overlap without emphysema (n=36)
Asthma-emphysema overlap (n=81)
Fig. 4. A non-proportional Venn diagram of the three phenotypes of elderly patients
with asthma, applied to that produced by the American Thoracic Society.18remodeling of the small airways is largely responsible for the
decline in lung function in COPD and long-standing asthma.25
COPD is substantially underdiagnosed26,27 and frequently mis-
diagnosed,28 with Soriano et al. showing that 72e93% of COPD
patients are not diagnosedwith their condition.27 Early diagnosis of
COPD has been attempted for high-risk patients29,30 and spirom-
etry was proven to play an important role in COPD screening and
early diagnosis. DLCO on pulmonary function tests and a higher rate
of airway-to-lung parenchymal abnormalities on lung imaging by
HRCT may also distinguish asthma from COPD.29 In this study, we
assessed DLCO and LAA severity to distinguish asthma-emphysema
(asthma-OAD with emphysema) from asthma-OAD without
emphysema. In multivariate logistic analysis, smoking status and
moderate or severe OADwere associatedwith emphysema on chest
HRCT in elderly patients with asthma.
The limitations of this study include the analysis of a relatively
small number of patients at a single center, which has a risk of
collection bias. However, our patients had almost similar airways to
those in Park et al. in a multicenter cohort,31 in which rates of
78.6%e75.0% for postbronchodilator %predicted FEV1 and 69.6%e
66.8% for the postbronchodilator FEV1/FVC ratio were found in
elderly patients with asthma (age65 years). This ﬁnding supports
the generalization of our results. Second, as our patients were
enrolled under the condition of treatments, there may be post-
treatment bias, such as some possibility of estimating low level of
FeNO in the patients with asthma-predominant.
In conclusion, half of elderly patients with asthma are charac-
terized by a comorbidity of emphysema. The phenotype with fea-
tures of asthma-emphysema overlap syndrome includes smokers
with asthma and nonsmokers with long-standing asthma who
progress to COPD. Further studies of the potential relationship of
onset of asthma and smoking status with the phenotype of asthma-
emphysema overlap are needed. In addition to the uncertainties in
the diagnostic criteria for ACOS, it is important to remember that
COPD is underdiagnosed in the elderly and that patients with
asthma-emphysema overlap are also at a higher risk of being falsely
classiﬁed as having airﬂow obstruction using the 70% ratio rec-
ommended by GOLD.
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